SGLT-2 Inhibitors and Nonalcoholic Fatty Liver Disease

In patients with diabetes, NAFLD regression was more likely with this drug class than with several others.

Many patients with type 2 diabetes also have nonalcoholic fatty liver disease (NAFLD), which can progress to fibrosis, cirrhosis, and cancer. In this retrospective study of 80,000 people (mean age, 59) with diabetes and presumed NAFLD, Korean researchers examined associations between liver-related outcomes and use of several oral diabetes drug classes, added to metformin. NAFLD was identified indirectly, using the fatty liver index (FLI) — a calculated score based on body-mass index, waist circumference, triglycerides, and serum γ-glutamyl transpeptidase level. At baseline, all patients had FLI scores ≥60 on a 100-point scale (considered to have high sensitivity for identifying NAFLD) and were taking metformin.

After a median 2.6 years of fo…

Reviewing Author

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

SGLT-2 Inhibitors and Nonalcoholic Fatty Liver Disease

Topics

Reviewing Author